Pfizer and its German partner on Tuesday announced they will work together on a shingles vaccine that utilizes messenger RNA technology. Pfizer and BioNTech created one of the most-used COVID-19 vaccines in the world by using the technology, which had never been cleared for use in any countries before the pandemic. Under a new agreement, Pfizer’s antigen and BioNTech’s mRNA platform will be combined while the companies will share development costs. Pfizer will pay BioNTech $225 million, while BioNTech will pay Pfizer $25 million. Pfizer will have rights to sell the vaccine globally while BioNTech will be able to market it in Germany, Turkey, and certain developing countries. Clinical trials are planned to start in the second half of this year. “Pfizer and BioNTech co-developed the world’s first mRNA vaccine, providing a well-tolerated and effective tool to help address COVID-19—the most devastating pandemic in a century—and demonstrating consistent, agile, and …